Please ensure Javascript is enabled for purposes of website accessibility

Why Innoviva Inc. Stock Jumped Tuesday

By Daniel Sparks – Feb 13, 2018 at 4:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An activist hedge fund is shaking things up at Innoviva.

What happened

Shares of biopharmaceutical company Innoviva (INVA -2.11%), which is primarily in the business of managing drug royalties it receives from major stakeholder and pharmaceutical company GlaxoSmithKline (GSK 0.24%), jumped as much as 11.2% on Tuesday.

The stock's gain follows an announcement that activist hedge fund Sarissa Capital has reached an agreement with Innoviva that will reconstitute its board of directors, including the addition of Jules Haimovitz and Sarah Schlesinger to its board. This is in addition to recently added Sarissa designees George Bickerstaff III and Odysseas Kostas to Innoviva's board. 

A blue background with an orange line chart showing the up and down movement of stocks.

Image source: Getty Images.

So what

Haimovitz and Schlesinger served together on ARIAD Pharmaceuticals' board and "were instrumental in the turnaround efforts at ARIAD which culminated in the sale of the company for over $5 billion last year," Sarissa Capital said in a Tuesday press release.

Sarissa had previously "accused the company of spending too much money on executive pay and board compensation," Reuters said. Sarissa Capital has a history of "shaking up boards in the pharmaceutical industry," Reuters also noted. 

Now what

With a replaced board, Sarissa "now plans to push for changes on how Innoviva spends money and consider moves such as share buybacks and dividend hikes," sources told Reuters.

In Innoviva's recently reported fourth quarter, net income attributable to shareholders was $58.4 million, up 129% year over year. In addition, it had just completed its capital return program, which included repurchasing $80 million worth of Innoviva common stock. 

Daniel Sparks has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Innoviva, Inc. Stock Quote
Innoviva, Inc.
INVA
$11.61 (-2.11%) $0.25
GSK Stock Quote
GSK
GSK
$29.43 (0.24%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.